Early investigations have revealed heightened levels of toxic metabolites in the neostriatum and neocortex of HD patients [113], as well as in the striatum and cortex of R6/2, YAC128, HdhQ92, and HdhQ111 HD mouse models [114], underscoring the potential significance of targeting KMO in the management of HD. This evidence concerns the gene KMO and Huntington disease.